The clinical study of CHOP combined with Rituximab in treating B-cell non-Hodgkin lymphoma

Objective To evaluate the efficacy and side-effects of CHOP combined with Rituximab(R-CHOP) in treating CD 20 positive B-cell non-Hodgkin lymphoma(NHL).Methods Applying the prospective study method with non-random and concurrent control,62 newly diagnosed patients with B-cell NHL were divided into two groups,R-CHOP group and CHOP group.34 cases in R-CHOP group were treated with R-CHOP while 28 cases in CHOP group were treated with CHOP.The efficacy and side-effects of these two groups were evaluated after 6 courses of treatment.Results The complete remission(CR) rate and total effective rate in R-CHOP group were 79.4%(27/34) and 91.2%(31/34),while the complete remission(CR) rate and total effective rate in CHOP group were 57.1%(16/28) and 71.4%(20/28).The efficacy differences between the two groups had statistical significance(P0.05) while the side-effects differences between the two groups had no statistical significance(P0.05).Conclusion Treating CD 20 positive B-cell NHL with R-CHOP is more effective,while there are no additional side-effects.